Myovant Sciences Ltd. (MYOV)

NYSE: MYOV · IEX Real-Time Price · USD
26.88
-0.02 (-0.07%)
Jan 27, 2023, 4:00 PM EST - Market closed
-0.07%
Market Cap 2.61B
Revenue (ttm) 379.11M
Net Income (ttm) -183.77M
Shares Out 97.10M
EPS (ttm) -1.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 535,588
Open 26.88
Previous Close 26.90
Day's Range 26.87 - 26.90
52-Week Range 7.67 - 27.03
Beta 2.20
Analysts Buy
Price Target 27.54 (+2.46%)
Earnings Date Jan 26, 2023

About MYOV

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduc... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Lynn Seely
Employees 579
Stock Exchange NYSE
Ticker Symbol MYOV
Full Company Profile

Financial Performance

In 2022, MYOV's revenue was $230.97 million, an increase of 289.39% compared to the previous year's $59.32 million. Losses were -$205.98 million, -19.27% less than in 2021.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for MYOV stock is "Buy." The 12-month stock price forecast is $27.54, which is an increase of 2.46% from the latest price.

Price Target
$27.54
(2.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 day ago - Zacks Investment Research

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

BASEL, Switzerland, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and men through purpose-driven science, empower...

1 day ago - GlobeNewsWire

MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Myovant Scienc...

2 days ago - Business Wire

MYOVANT SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV

NEW ORLEANS , Jan. 11, 2023 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

2 weeks ago - PRNewsWire

MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences

NEW YORK , Dec. 16, 2022 /PRNewswire/ -- Shareholder rights law firm Julie & Holleman is investigating the proposed acquisition of Myovant Sciences (NYSE: MYOV) by affiliates of its controlling shareh...

1 month ago - PRNewsWire

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, emp...

2 months ago - GlobeNewsWire

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms...

2 months ago - GlobeNewsWire

Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced the launch of Time To GoTM today, a multi-channel educationa...

2 months ago - Business Wire

SHAREHOLDER ALERT: Weiss Law Reminds MYOV, KNBE, LMST, and PEBO Shareholders About Its Ongoing Investigations

NEW YORK , Nov. 1, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights ...

Other symbols: KNBELMSTPEBO
3 months ago - PRNewsWire

Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates

Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022

BASEL, Switzerland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, emp...

3 months ago - GlobeNewsWire

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Myovant Sciences Ltd. - MYOV

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...

3 months ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates Myovant Sciences Ltd.

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Myovant Sciences Ltd. ("Myovant" or the...

3 months ago - PRNewsWire

Myovant Sciences Cancels Second Quarter Earnings Conference Call

BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 202...

3 months ago - GlobeNewsWire

MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences

Today's market-moving news in the drugmaker sector is that Sumitomo Pharma and a subsidiary have agreed to buy out the remainder of Myovant Sciences (NYSE: MYOV) that they don't already own. Furtherm...

3 months ago - InvestorPlace

Why Myovant Sciences Stock Is Moving Higher - Myovant Sciences (NYSE:MYOV)

Myovant Sciences Ltd (NYSE: MYOV) shares are trading higher Monday after the company announced it will be acquired by Sumitovant Biopharma for $27 per share in cash.

3 months ago - Benzinga

Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion

Shares of Myovant Sciences Ltd. MYOV, +0.95% were up 8.2% in premarket trading on Monday, the day after the company said it will be acquired by Sumitomo Pharma Co. Ltd.

3 months ago - Market Watch

MYOV STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Myovant Sciences Ltd. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Myovant Sciences Ltd.

3 months ago - Business Wire

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women's Health and Prostate C...

3 months ago - PRNewsWire

CORRECTION -- Myovant Sciences, Inc.

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier today b...

3 months ago - GlobeNewsWire

Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for i...

3 months ago - GlobeNewsWire

Myovant stock opened 35% up on Monday: here's the catalyst

Myovant Sciences Ltd (NYSE: MYOV) opened nearly 35% up on Monday after the biopharmaceutical company said it rejected a buyout proposal from its largest shareholder. Myovant is open to considering a b...

4 months ago - Invezz

Why Is Myovant Sciences (MYOV) Stock Up 30% Today?

Myovant Sciences (NYSE: MYOV) stock is skyrocketing over 30% today on news that the British biopharmaceutical company has received a buyout offer. MYOV stock surged as much as 31% in premarket tradin...

4 months ago - InvestorPlace

Myovant Stock Soars After Rejecting $2.5 Billion Sumitomo Bid

The offer came at a 27% premium to Myovant's previous market price but was below the company's trading highs last year.

4 months ago - Barrons